Hypercoagulability in sickle cell disease: new approaches to an old problem.
about
Negative health implications of sickle cell trait in high income countries: from the football field to the laboratoryTissue factor and thrombin in sickle cell anemiaMEK inhibitors, novel anti-adhesive molecules, reduce sickle red blood cell adhesion in vitro and in vivo, and vasoocclusion in vivoBiomarkers and recent advances in the management and therapy of sickle cell diseaseMycoplasma suis infection results endothelial cell damage and activation: new insight into the cell tropism and pathogenicity of hemotrophic mycoplasma.Thrombotic microangiopathy in sickle cell disease crisis.Evaluating the safety and effectiveness of venous thromboembolism prophylaxis in patients with sickle cell disease.Treating sickle cell disease by targeting HbS polymerizationPlacenta growth factor (PlGF), a novel inducer of plasminogen activator inhibitor-1 (PAI-1) in sickle cell disease (SCD).Association of coagulation activation with clinical complications in sickle cell diseaseAcute chest syndrome: sickle cell disease.Association of pro-inflammatory high-density lipoprotein cholesterol with clinical and laboratory variables in sickle cell diseaseVenous thromboembolism incidence in the Cooperative Study of Sickle Cell Disease.Clinical biomarkers in sickle cell disease.Involvement of miR-30c and miR-301a in immediate induction of plasminogen activator inhibitor-1 by placental growth factor in human pulmonary endothelial cells.The spleen in the sickling disorders: an update.Prospective study of sickle cell trait and venous thromboembolism incidenceCoagulation activation in children with sickle cell disease is associated with cerebral small vessel vasculopathy.Sickle cell disease and venous thromboembolism: what the anticoagulation expert needs to knowSickle cell disease in pregnancy: maternal complications in a Medicaid-enrolled populationSickle-cell trait: novel clinical significance.Coagulopathy and functional hyposplenism during an episode of thrombotic thrombocytopenic purpura in a HgbS/β (+)-thalassemia patient.Tissue factor promotes activation of coagulation and inflammation in a mouse model of sickle cell diseaseGenetic diminution of circulating prothrombin ameliorates multiorgan pathologies in sickle cell disease miceHbS Binding to GP1bα Activates Platelets in Sickle Cell DiseaseCharacterization of the hypercoagulable state in patients with sickle cell disease.Prothrombin activation in blood coagulation: the erythrocyte contribution to thrombin generation.Hypercoagulability in congenital haemolytic anaemiasGenetic variants at HbF-modifier loci moderate anemia and leukocytosis in sickle cell disease in TanzaniaNeutrophils, platelets, and inflammatory pathways at the nexus of sickle cell disease pathophysiology.Beyond hydroxyurea: new and old drugs in the pipeline for sickle cell disease.A double-blind, randomized, multicenter phase 2 study of prasugrel versus placebo in adult patients with sickle cell disease.Coagulation activation in sickle cell trait: an exploratory studyClinical correlates of acute pulmonary events in children and adolescents with sickle cell diseaseCoagulation abnormalities of sickle cell disease: Relationship with clinical outcomes and the effect of disease modifying therapies.Vascular complications after splenectomy for hematologic disorders.Differential contribution of FXa and thrombin to vascular inflammation in a mouse model of sickle cell disease.Role of the hemostatic system on sickle cell disease pathophysiology and potential therapeuticsInterplay between coagulation and vascular inflammation in sickle cell disease.Global assays of hemostasis.
P2860
Q26862794-378DE7DA-F7D0-4F15-BE5D-4621E1254831Q27024887-DEB3615E-5C80-45FE-9F4D-7BBFDF504C1EQ27335195-0F4B4CE0-C865-4599-B9A6-AC68EC5453F4Q28082462-8989F5D8-3F95-4EB4-8535-CC069A554399Q30536157-CCDAF410-275A-4B42-BC5F-81F497643C2BQ33404745-DC01508A-B2A1-4562-BB5A-BBDFB9F1E29FQ33437543-9468A022-0F0F-4111-BC71-B662BF2F52A2Q33707352-B5AAC6FB-77C9-4D4F-92B7-21B0DE8E2334Q33883207-D8D9C871-FBB1-4C6B-9D55-2D4AF08D0EC7Q34130633-BF5EF0C8-4109-49DF-8CAC-AE25AF3BDE9CQ34187526-F9969887-27BE-453B-8CA6-58823A17ADCDQ34466198-72E61874-F0F1-45E4-A317-5B9A1180BACCQ34718108-7E043F53-44AB-4439-930C-EAD90E0B6B43Q34800466-0DE5A74B-AAA9-42EF-B30A-DC9CF9392CC7Q34806514-900F2357-4AFE-48C8-9BCD-5C40DBA6F731Q34877934-AC9DCE42-9C90-44DE-BAE1-4D86E64F3628Q34964268-090BB258-B761-4BE0-8930-A230D55CE62DQ35036717-792EC131-420E-46D6-839A-118330117BA8Q35105431-C5E5EFDF-1F46-4692-97C2-9645324BDB40Q35379403-7EE4B943-4A68-47D5-90F6-5635AD9E2A3CQ35820449-047F5C9C-52CF-4316-8E42-5D90E51BFAFAQ35924832-C6E01A9C-1303-4777-957F-76B64BF4AEDBQ36106316-B29B6D12-C241-410D-8AB2-78858D83870CQ36143261-9DBE36AD-59EF-4E74-8F15-2E23961DCA0FQ36218323-C80DB253-7BAB-4DAE-87D6-F1D0DB4EB1F3Q36328563-D018BC8D-F5DD-46A6-91F8-8A38B4B9F97AQ36370881-E197B316-90FD-4D58-A956-F052B96CCEA0Q36393525-C1F1EA1C-0910-48BE-885A-2597637E1671Q36532564-188D80B6-0EE8-4BD6-9945-4CA089F35D19Q36596850-008B5504-EC54-41A5-BA11-5751481CC36CQ36596855-F76BA07C-12B2-490F-A08F-0855EFF5DCF4Q36649213-A025E66B-F94F-405F-A9F1-EED35025F805Q36661960-F7533F80-6B03-4AF0-85FC-C76F2F96F79AQ36947395-3A8E1752-F5F5-4F83-BE56-E2463764D92FQ37033939-7BF3D907-1371-496C-AB0B-0F4912298304Q37373000-E1D78FD7-D21B-4700-ADA3-0CF9D8A892A3Q37636986-481A430D-01E3-443E-94D7-3E3C2286963AQ37700095-47A46761-9BF0-4692-9DD2-42A2168B44E8Q38099667-CCF5C87E-9E26-4A4D-8B3E-78424CC25B59Q38233155-343B5DFE-7A8C-486F-803B-E796C6CE0EBE
P2860
Hypercoagulability in sickle cell disease: new approaches to an old problem.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on January 2007
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Hypercoagulability in sickle cell disease: new approaches to an old problem.
@en
Hypercoagulability in sickle cell disease: new approaches to an old problem.
@nl
type
label
Hypercoagulability in sickle cell disease: new approaches to an old problem.
@en
Hypercoagulability in sickle cell disease: new approaches to an old problem.
@nl
prefLabel
Hypercoagulability in sickle cell disease: new approaches to an old problem.
@en
Hypercoagulability in sickle cell disease: new approaches to an old problem.
@nl
P1476
Hypercoagulability in sickle cell disease: new approaches to an old problem.
@en
P2093
Kenneth I Ataga
Nigel S Key
P356
10.1182/ASHEDUCATION-2007.1.91
P577
2007-01-01T00:00:00Z